Adults 18 years and older may qualify for a study evaluating an investigational oral study medication for elevated lipoprotein(a) [Lp(a)], a type of cholesterol-related particle linked to cardiovascular risk.
Lipoprotein Study
Age Range:
18
Gender:
Male and Female
Location:
Rochester, New York
About the Study
This research study is evaluating an investigational study medication called muvalaplin. The purpose is to assess whether muvalaplin can help reduce the risk of major adverse cardiovascular events in adults with elevated Lp(a) who have either had a prior atherosclerotic cardiovascular event or are at risk for a first cardiovascular event.
Qualifications
You may be able to join if you:
- Are 18 years of age or older.
- Have elevated Lp(a) based on study testing.
- Have had a prior cardiovascular event, or have risk factors that may place you at risk for a first cardiovascular event.
- Are willing to attend study visits and follow study procedures for the duration of the study.
- Are on stable doses of certain cholesterol-lowering medications, if applicable.
- Do not have a recent major cardiovascular event, such as heart attack or stroke.
- Do not have uncontrolled high blood pressure, severe kidney problems, or certain other serious medical conditions.
- Are not currently pregnant or breastfeeding.
FEATURED STUDIES
Adults 18 years of age and older with elevated inflammation levels and heart disease or certain health conditions that increase […]
An upcoming clinical research study is evaluating an investigational treatment designed to help prevent the flu in adults who may […]
An upcoming clinical research study is evaluating an investigational vaccine designed to help prevent illness caused by norovirus in adults […]
An upcoming clinical research study is evaluating an investigational long-acting approach designed to help prevent influenza. Join our interest list […]
Adults 65 and older may qualify for a clinical research study evaluating an investigational seasonal flu vaccine.
This clinical trial will help us learn if receiving another dose of the RSV vaccine is safe and can help […]